GDI2

Across TCGA pan-cancer cohorts, GDI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GDI2 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GDI2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GDI2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where GDI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.644	0.405	<.001	68	view →
LUAD	DFS	Quartile	III,IV	0.198	0.767	.004	13	view →
HNSC	DFS	Median	III,IV	0.935	1.000	.029	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.699	0.145	.042	2	view →
LSCC	DFS	Median	III,IV	0.620	0.924	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GDI2–PDAC (OS)

Open the PDAC breakdown →